Tebentafusp Represents a Potential Frontline Therapy for Patients with Uveal Melanoma

Source: OncLive, December 2021

Richard D. Carvajal, MD, discusses the need for additional treatment options in patients with rare melanomas, the promise of tebentafusp, and ongoing trials in the pipeline for this patient population.

In findings from a recent phase 3 clinical trial (NCT03070392), the novel bispecific fusion protein tebentafusp (IMCgp100) showed statistically significant improvements in overall survival for patients with uveal melanoma, according to Richard D. Carvajal, MD.

Carvajal added that the treatment paradigm for patients with uveal and other rare, non-cutaneous melanomas has remained stagnant. However, he said the PDUFA date for tebentafusp is February, and the drug’s approval could provide a big benefit in an area where there have been few effective, FDA-approved therapies.

READ THE ORIGINAL FULL ARTICLE

 

26/1